Compare SEB & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEB | ACAD |
|---|---|---|
| Founded | 1918 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.3B |
| IPO Year | 1994 | 2000 |
| Metric | SEB | ACAD |
|---|---|---|
| Price | $4,187.27 | $28.63 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 22 |
| Target Price | N/A | ★ $30.55 |
| AVG Volume (30 Days) | 3.3K | ★ 1.6M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.17% | N/A |
| EPS Growth | ★ 467.71 | 69.12 |
| EPS | ★ 283.99 | 0.20 |
| Revenue | ★ $5,809,000,000.00 | $726,437,000.00 |
| Revenue This Year | N/A | $18.80 |
| Revenue Next Year | N/A | $11.70 |
| P/E Ratio | ★ $15.07 | $142.25 |
| Revenue Growth | 7.99 | ★ 40.45 |
| 52 Week Low | $3,140.01 | $19.69 |
| 52 Week High | $5,989.37 | $29.48 |
| Indicator | SEB | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Seaboard Corp is a diversified group of companies that operate in agricultural, energy, and ocean transport businesses. The company is engaged in hog production, biofuel production, and pork processing in the United States; commodity trading and grain processing in Africa and South America; cargo shipping services in the U.S., Caribbean and Central and South America; sugar and alcohol production in Argentina; and electric power generation in the Dominican Republic. It also has an equity method investment in Butterball, LLC, a producer and processor of turkey products. The group's operating segments are; pork, commodity trading and milling, marine, liquid fuels, power, turkey, and others. It operates in 45 countries, with a concentration in the Caribbean, Central and South American region.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.